Real Talk-- Why Do Some Commercial Biotech Companies Trade on Trailing Revenue Instead of Forward Guidance?

Over the past year I’ve noticed something unusual with a subset of small commercial-stage biotech companies. Unlike most sectors, which generally trade on 12 to 24 month forward revenue, early commercial biotechs often get valued almost entirely on their most recent quarter. This creates situations where companies with FDA approval, real product sales, and multi-year cash runways still get priced as if nothing meaningful is expected to change in the next year or two.

One example I came across was a company that launched a symptomatic Alzheimer’s drug called Zunveyl into long-term care earlier this year. They reported a little over $2.6 million in product revenue last quarter, and early adoption from facilities has been steady, but the valuation still appears anchored to trailing numbers rather than the trajectory implied by improving payer access and repeat ordering, solid QoQ growth.

It made me wonder whether this is a broader structural pattern in early commercial biotech, where the shift from a “pipeline story” to real revenue causes the market to fixate on quarter-to-quarter noise. In most other industries, companies tend to trade on future revenue rather than the most recent quarter, so I’m curious why this disconnect seems so common in biotech.

Is this caution justified, or is it an inefficiency in how the market prices companies in the early commercialization phase?